ID   D283 Med
AC   CVCL_1155
SY   D283 MED; D283-MED; D283_Med; D-283 Med; D-283 Med-C; D-283MED; D283MED; D283Med; D283-Med; D-283; D283; Med 283; H283
DR   BTO; BTO:0005135
DR   CLO; CLO_0002673
DR   EFO; EFO_0002156
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-185
DR   BioGRID_ORCS_Cell_line; 438
DR   BioSample; SAMN03472736
DR   BioSample; SAMN10987924
DR   cancercelllines; CVCL_1155
DR   CCRID; 1101HUM-PUMC000341
DR   Cell_Model_Passport; SIDM00888
DR   ChEMBL-Cells; CHEMBL3307938
DR   ChEMBL-Targets; CHEMBL614476
DR   CLS; 300330
DR   Cosmic; 687772
DR   Cosmic; 906834
DR   Cosmic; 923656
DR   Cosmic; 973261
DR   Cosmic; 974280
DR   Cosmic; 975024
DR   Cosmic; 1995381
DR   Cosmic; 2362650
DR   Cosmic; 2731179
DR   Cosmic-CLP; 906834
DR   DepMap; ACH-000055
DR   EGA; EGAS00001000978
DR   GDSC; 906834
DR   GEO; GSM383762
DR   GEO; GSM482336
DR   GEO; GSM886969
DR   GEO; GSM888038
DR   GEO; GSM918116
DR   GEO; GSM919357
DR   GEO; GSM1234974
DR   GEO; GSM1234975
DR   GEO; GSM1669717
DR   IARC_TP53; 21296
DR   IGRhCellID; D283Med
DR   IZSLER; BS TCL 203
DR   KCB; KCB 2010201YJ
DR   LiGeA; CCLE_487
DR   LINCS_LDP; LCL-1577
DR   Lonza; 654
DR   PharmacoDB; D283MED_273_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1155
DR   PubChem_Cell_line; CVCL_1155
DR   Wikidata; Q54817202
RX   DOI=10.1007/0-306-46861-1_11;
RX   PubMed=1822845;
RX   PubMed=2180567;
RX   PubMed=3103453;
RX   PubMed=4056828;
RX   PubMed=12973738;
RX   PubMed=16946619;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20847082;
RX   PubMed=21177782;
RX   PubMed=22460905;
RX   PubMed=24297863;
RX   PubMed=24300787;
RX   PubMed=27397505;
RX   PubMed=27498314;
RX   PubMed=27812533;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31963405;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Genome ancestry: African=1.87%; Native American=0%; East Asian, North=1.34%; East Asian, South=0%; South Asian=0%; European, North=63.61%; European, South=33.18% (PubMed=30894373).
CC   Misspelling: D283 MR; Note=Occasionally.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC; CCRID; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 9,12
ST   D13S317: 8,10
ST   D16S539: 11
ST   D19S433: 13,14
ST   D21S11: 28,30.2
ST   D2S1338: 17,23
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 12,13
ST   FGA: 20,23
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C129445; Medulloblastoma, non-WNT/non-SHH, group 3
DI   ORDO; Orphanet_616; Medulloblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   6Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=1822845;
RA   Wikstrand C.J., Friedman H.S., Bigner D.D.;
RT   "Medulloblastoma cell-substrate interaction in vitro.";
RL   Invasion Metastasis 11:310-324(1991).
//
RX   PubMed=2180567;
RA   Bigner S.H., Friedman H.S., Vogelstein B., Oakes W.J., Bigner D.D.;
RT   "Amplification of the c-myc gene in human medulloblastoma cell lines
RT   and xenografts.";
RL   Cancer Res. 50:2347-2350(1990).
//
RX   PubMed=3103453;
RA   Trojanowski J.Q., Friedman H.S., Burger P.C., Bigner D.D.;
RT   "A rapidly dividing human medulloblastoma cell line (D283 MED)
RT   expresses all three neurofilament subunits.";
RL   Am. J. Pathol. 126:358-363(1987).
//
RX   PubMed=4056828; DOI=10.1097/00005072-198511000-00005;
RA   Friedman H.S., Burger P.C., Bigner S.H., Trojanowski J.Q.,
RA   Wikstrand C.J., Halperin E.C., Bigner D.D.;
RT   "Establishment and characterization of the human medulloblastoma cell
RT   line and transplantable xenograft D283 Med.";
RL   J. Neuropathol. Exp. Neurol. 44:592-605(1985).
//
RX   PubMed=12973738; DOI=10.1002/pmic.200300460;
RA   Peyrl A., Krapfenbauer K., Slavc I., Yang J.-W., Strobel T., Lubec G.;
RT   "Protein profiles of medulloblastoma cell lines DAOY and D283:
RT   identification of tumor-related proteins and principles.";
RL   Proteomics 3:1781-1800(2003).
//
RX   PubMed=16946619; DOI=10.1159/000095545;
RA   Dharmaraj P., Ball S., Johnstone H., Bailey S., Clifford S.C.,
RA   Hale J., Cheetham T.D.;
RT   "Hypercalcaemia in relapsed medulloblastoma 8 years post-diagnosis;
RT   evidence to support PTHrP production by medulloblastoma cells.";
RL   Horm. Res. 66:268-272(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20847082; DOI=10.1093/neuonc/noq091;
RA   Teider N., Scott D.K., Neiss A., Weeraratne S.D., Amani V.M., Wang Y.-F.,
RA   Marquez V.E., Cho Y.-J., Pomeroy S.L.;
RT   "Neuralized1 causes apoptosis and downregulates Notch target genes in
RT   medulloblastoma.";
RL   Neuro-oncol. 12:1244-1256(2010).
//
RX   PubMed=21177782; DOI=10.1093/neuonc/noq179;
RA   Weeraratne S.D., Amani V.M., Neiss A., Teider N., Scott D.K.,
RA   Pomeroy S.L., Cho Y.-J.;
RT   "miR-34a confers chemosensitivity through modulation of MAGE-A and p53
RT   in medulloblastoma.";
RL   Neuro-oncol. 13:165-175(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24297863; DOI=10.1158/1078-0432.CCR-13-2281;
RA   Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S.,
RA   Tang Y.-J., Bolin S., Schumacher S.E., Zeid R., Masoud S., Yu F.-R.,
RA   Vue N., Gibson W.J., Paolella B.R., Mitra S.S., Cheshier S.H., Qi J.,
RA   Liu K.-W., Wechsler-Reya R.J., Weiss W.A., Swartling F.J., Kieran M.W.,
RA   Bradner J.E., Beroukhim R., Cho Y.-J.;
RT   "BET bromodomain inhibition of MYC-amplified medulloblastoma.";
RL   Clin. Cancer Res. 20:912-925(2014).
//
RX   PubMed=24300787; DOI=10.1158/1078-0432.CCR-13-2053;
RA   Erdreich-Epstein A., Robison N., Ren X.-H., Zhou H., Xu J.-Y.,
RA   Davidson T.B., Schur M., Gilles F.H., Ji L.-Y., Malvar J.,
RA   Shackleford G.M., Margol A.S., Krieger M.D., Judkins A.R., Jones D.T.W.,
RA   Pfister S.M., Kool M., Sposto R., Asgharzadeh S.;
RT   "PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors
RT   and gliomas.";
RL   Clin. Cancer Res. 20:827-836(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27498314; DOI=10.1016/j.jbiotec.2016.07.028;
RA   Ivanov D.P., Coyle B., Walker D.A., Grabowska A.M.;
RT   "In vitro models of medulloblastoma: choosing the right tool for the
RT   job.";
RL   J. Biotechnol. 236:10-25(2016).
//
RX   PubMed=27812533; DOI=10.1016/j.dib.2016.10.004;
RA   Ivanov D.P., Walker D.A., Coyle B., Grabowska A.M.;
RT   "Data on the number and frequency of scientific literature citations
RT   for established medulloblastoma cell lines.";
RL   Data Brief 9:696-698(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31963405; DOI=10.3390/cancers12010226;
RA   Casciati A., Tanori M., Manczak R., Saada S., Tanno B., Giardullo P.,
RA   Porcu E., Rampazzo E., Persano L., Viola G., Dalmay C., Lalloue F.,
RA   Pothier A., Merla C., Mancuso M.;
RT   "Human medulloblastoma cell lines: investigating on cancer stem
RT   cell-like phenotype.";
RL   Cancers (Basel) 12:226.1-226.14(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//